Risankizumab 600mg/10ml solution for infusion vials
NHS hospitals in England used £41,264,138 of indicative cost of Risankizumab 600mg/10ml solution for infusion vials in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 11.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Risankizumab 600mg/10ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Risankizumab 600mg/10ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Salford Royal Nhs Foundation Trust | £1,789,436 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,480,110 |
| London North West Healthcare Nhs Trust | £1,480,110 |
| University College London Foundation Tr | £1,237,305 |
| Barts Health Nhs Trust | £1,180,762 |
| Univ Hpls Bristol Nhs Foundation Trust | £1,031,088 |
| Western Sussex Hospitals Nhs Found Trust | £997,827 |
| North Bristol Nhs Trust | £961,240 |
| University Hpls Of Leicester Nhs Trust | £901,370 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £888,066 |
The primary-care picture
Risankizumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Risankizumab medicine page.